Abstract:Teena Jacob Chirayil, 1, 2 G S Vinod Kumar 1 1 Nano Drug Delivery Systems (NDDS), Cancer Biology Division, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India; 2 Research Scholar, Department of Biotechnology, University of Kerala, Thiruvananthapuram, Kerala, India Correspondence: G S Vinod Kumar, Tel +91 471 2781217, Email Purpose: This study aimed to design a prototypic drug delivery system (DDS) made of an amphiphilic, pullulan (Pull)-derived biodegradable polymer for targeting the asialoglycoprotein receptor (ASGPR) overexpressed in HCC. Stearic acid (SA) was conjugated to increase the hydrophobicity of pullulan (Pull-SA). Methods: Pullulan (Pull) was linked to stearic acid (SA) after functional group modifications via EDC/NHS chemistry and characterized. Sorafenib tosylate (SRFT) was entrapped in pullulan–stearic acid nanoparticles (Pull-SA-SRFT) and its particle size, zeta potential, entrapment efficiency (EE), loading capacity (LC), and release efficiency was measured. The competence of Pull-SA-SRFT over SRFT in vitro was assessed using the ASGPR over-expressing PLC/PRF/5 hepatocellular carcinoma (HCC) cell line. This was done by studying cytotoxicity by MTT assay and chromosome condensation assay, early apoptosis by annexin-Pi staining, and late apoptosis by live–dead assay. The cellular uptake study was performed by incorporating coumarin-6 (C6) fluorophore in place of SRFT in Pull-SA conjugates. A biodistribution study was conducted in Swiss-albino mice to assess the biocompatibility and targeting properties of SRFT and Pull-SA-SRFT to the liver and other organs at 1, 6, 24, and 48 h. Results: The characterization studies of the copolymer confirmed the successful conjugation of Pull-SA. The self-assembled amphiphilic nanocarrier could proficiently entrap the hydrophobic drug SRFT to obtain an entrapment efficiency of 95.6% (Pull-SA-SRFT). Characterization of the synthesized nanoparticles exhibited highly desirable nanoparticle characteristics. In vitro, apoptotic studies urged that Pull-SA-SRFT nanoparticle was delivered more efficiently to HCC than SRFT. The cellular uptake study performed, gave propitious results in 4 hrs. The biodistribution study conducted in immunocompetent mice suggested that Pull-SA-SRFT was delivered more than SRFT to the liver when compared to other organs, and that the system was biocompatible. Conclusion: Pull-SA-SRFT is a promisingly safe, biodegradable, cell-specific nanocarrier and a potential candidate to target hydrophobic drugs to HCC. Graphical Keywords: pullulan stearic acid nanoparticles, hepatocellular carcinoma, drug delivery system Graphical Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer and the world's second-biggest cause of cancer-related fatalities. 1,2 The incidence of HCC is more prevalent in patients with chronic liver disease, such as chronic hepatitis (B and C), liver cirrhosis, fatty liver disease, exposure to aflatoxin, and excess consumption of alcohol. 3–6 Medical treatments such as chemotherapy, chemoembolization, ablation, and proton beam therapy have been ineffective for these patients and the majority of them show disease recurrence, rapid progression, and metastases. 7,8 Despite various advancements, pharmacological therapy has had a limited therapeutic impact. 9 The majority of anti-cancer medications have high toxicity and low specificity, resulting in systemic toxicity and severe side effects. Due to the lack of effective therapeutic possibilities, the pursuit of alternative pharmaceutical therapies is therefore particularly pressing. Sorafenib tosylate (Nexavar, BAY-43-9006), the currently FDA-approved drug for the standard treatment of HCC is a multikinase inhibitor that blocks the RAF/MEK/ERK pathway in tumor cells. 10 It interferes with cell proliferation and angiogenesis by inhibiting serine/threonine kinases (c-RAF) as well as the receptor tyrosine kinases vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR3, platelet-derived growth factor receptor (PDGFR), FLT3, Ret and c-KIT. 11–13 The recommended dose of Nexavar in adults is 400 mg twice daily (a total daily dose of 800 mg) 14 leading to severe diarrhea resulting in excretion of high amounts of the drug. 13 Regardless of its efficacy, it leads to severe side effects such as nausea, vomiting, high arterial pressure and hand-foot skin reactions. 15 Polymeric nanoparticles (NPs) have been used as promising anticancer drug carriers, 16 working as long-acting, regulated, and targeted drug delivery systems that boost therapeutic effects while minimising n -Abstract Truncated-

Sorafenib-Entrapped, Self-Assembled Pullulan–Stearic Acid Biopolymer-Derived Drug Delivery System to PLC/PRF/5 Hepatocellular Carcinoma Model

Dual GSH-exhausting Sorafenib Loaded Manganese-Silica Nanodrugs for Inducing the Ferroptosis of Hepatocellular Carcinoma Cells.

Sorafenib Encapsulated in Nanocarrier Functionalized with Glypican-3 Specific Peptide for Targeted Therapy of Hepatocellular Carcinoma.

Sorafenib-Loaded PLGA-TPGS Nanosystems Enhance Hepatocellular Carcinoma Therapy Through Reversing P-Glycoprotein-Mediated Multidrug Resistance

Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment

Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma

Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors

Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis

RSM-CCD optimized hollow mesoporous silica nanospheres encapsulating sorafenib induce mitochondrial membrane potential-mediated apoptotic cell death in non-small cell lung cancer

Polylactide-tethered Prodrugs in Polymeric Nanoparticles As Reliable Nanomedicines for the Efficient Eradication of Patient-Derived Hepatocellular Carcinoma

Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment

CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma

Co‐Delivery of siNRF2 and Sorafenib by a “Click” Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma

Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[ε-caprolactone-co-(12-hydroxystearate)] Copolymer

Preparation of Glutathione-Regulated Sorafenib Targeted Nanodrug Delivery System and Its Antihepatocellular Carcinoma Activity

Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study

Investigation of Dual-Loaded Doxorubicin and Sorafenib Liposomes Co-Modified with Glycyrrhetinic Acid and Cell-Penetrating Peptide TAT

Sorafenib and tetrakis (4-carboxyphenyl) porphyrin assembled nanoparticles for synergistic targeted chemotherapy and sonodynamic therapy of hepatocellular carcinoma

Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo

Fabrication of polymeric sorafenib coated chitosan and fucoidan nanoparticles: Investigation of anticancer activity and apoptosis in colorectal cancer cells

A Polymeric Nanoparticle Formulation of Curcumin in Combination with Sorafenib Synergistically Inhibits Tumor Growth and Metastasis in an Orthotopic Model of Human Hepatocellular Carcinoma